In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
All content for Biotech Bulls & Breakthroughs is the property of BioPharmCatalyst and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
Ep. 2: The Future of Oncology: Key Takeaways from ASCO | Biotech Bulls & Breakthroughs Podcast
Biotech Bulls & Breakthroughs
40 minutes
5 months ago
Ep. 2: The Future of Oncology: Key Takeaways from ASCO | Biotech Bulls & Breakthroughs Podcast
In this episode, John Gagliano and Sheff discuss the recent ASCO conference, its significance in the oncology space, and key takeaways from the event. They delve into the importance of biotech conferences for investors, analyze oncology companies and their drug development strategies, and explore investment strategies focusing on smaller biotech firms. The conversation also touches on the role of AI in drug development and highlights current watchlist stocks with upcoming catalysts. In this ...
Biotech Bulls & Breakthroughs
In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
